Healthcare Equipment and Supplies
Company Overview of REVA Medical, Inc.
REVA Medical, Inc., a development stage medical device company, focuses on the commercialization of minimally invasive medical devices for the treatment of coronary artery disease in the human heart. It is developing and testing a bioresorbable stent to treat vascular disease in humans under the Fantom scaffolds name. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.
5751 Copley Drive
San Diego, CA 92111
Founded in 1998
Key Executives for REVA Medical, Inc.
Co-founder, Chairman and Chief Executive Officer
Total Annual Compensation: $430.5K
President and Chief Operating Officer
Total Annual Compensation: $447.1K
Chief Financial Officer and Company Secretary
Total Annual Compensation: $515.2K
Senior Vice President of Clinical and Regulatory Affairs
Total Annual Compensation: $353.7K
Senior Vice President of Product Development
Total Annual Compensation: $348.7K
Compensation as of Fiscal Year 2014.
REVA Medical, Inc. Key Developments
REVA Medical, Inc. Announces Unaudited Consolidated Cash Flow Results for the Second Quarter and Year to Date Ended June 30, 2015
Jul 31 15
REVA Medical, Inc. announced unaudited consolidated cash flow results for the second quarter and year to date ended June 30, 2015. For the quarter, the company reported net operating cash outflow of USD 4,476,000.
For the year to date, the company reported net operating cash outflow of USD 9,437,000.
REVA Medical, Inc. Releases Initial Clinical Results for Fantom Scaffold
May 21 15
REVA Medical, Inc. released initial clinical data on a subset of patients treated with the Fantom sirolimus-eluting bioresorbable scaffold at the Paris Course on Revascularization (EuroPCR). The FANTOM I pilot clinical trial, which enrolled patients with the Fantom scaffold at two clinical sites in Brazil and Poland, was designed to provide early clinical data on the device. In these patients acute performance was demonstrated with 100% technical and procedural success and no reported Major Adverse Cardiac Events (MACE) to date, with no incidence of ischemic target lesion revascularization (TLR), myocardial infarction (heart attack) or stent thrombosis. REVA is currently enrolling patients in the FANTOM II trial, which is designed to provide the necessary data for a European CE Mark application of Fantom.
Reva Medical, Inc. Expands FANTOM II Clinical Trial to Australia
May 15 15
REVA Medical, Inc. announced that the FANTOM II clinical trial is now enrolling patients with the Fantom sirolimus-eluting bioresorbable scaffold in Australia. This is in addition to previously announced sites in Brazil and Europe. The Fantom scaffold, made from REVA's advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time. The FANTOM II trial is enrolling patients to support a European CE Mark application, which is expected to occur by mid-2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|